Percutaneous mitral valve therapy: when? Which patients?
Transcatheter management of valvular heart disease is an emerging area of intense interest. Patients with mitral regurgitation present a large clinical unmet need for therapeutic advances. A large randomized, pivotal trial of one device, which performs an edge-to-edge repair, has recently completed enrollment and is awaiting all patients to reach the primary clinical endpoint. A host of other devices are still in preclinical or early clinical feasibility trials after having undergone device iteration. Clinical trials with two devices have been stopped because of disappointing early results. Although the field of transcatheter treatment of aortic stenosis is proceeding at a brisk pace with commercial approval of two devices in Europe, percutaneous treatment of mitral regurgitation has progressed at a much more measured pace because of varying cause of the disease, complexity of valvular anatomy, imaging, and delivery issues.